Cynata Therapeutics to begin stem cell product trial in England – Proactive Investors Australia
Proactive Investors Australia |
Cynata Therapeutics to begin stem cell product trial in England
Proactive Investors Australia Cynata Therapeutics (ASX:CYP) has received approval from the National Health Service (NHS), England for the Phase 1 trial in patients with steroid-resistant acute GvHD (graft versus host disease). Cynata Therapeutics to begin stem cell product trial in … |
